Page 16 - Evidence Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article HOUSTON, April 20, 2021 /PRNewswire/ --  Nuo Therapeutics, Inc. (OTC Pink: AURX) ("Nuo" or the "Company"), today announced the recent publication of the final decision memo for Autologous Blood-Derived Products for Chronic Non-Healing Wounds (CAG-00190R4).  On April 13, 2021, Centers for Medicare & Medicaid Services (CMS) concluded in its final coverage decision memo (available at the URL at the bottom of this release) that Medicare will cover autologous platelet-rich plasma (PRP) for treatment of chronic non-healing diabetic wounds (DFUs) under section 1862(a)(1)(A) of t...

email article Medicare reimbursement for transcatheter mitral valve repair (TMVR) was extended to include secondary (functional) mitral regurgitation resulting from heart failure, according to a revised National Coverage Determination (NCD). The Centers for Medicare & Medicaid Services (CMS) renamed the TMVR NCD to cover "mitral valve Transcatheter Edge-to-Edge Repair" for people with secondary mitral regurgitation who remain symptomatic despite guideline-directed medical therapy. Notably, registry participation continues to be required as part of the Coverage with Evidence Development ...

POLITICO Get the Prescription Pulse newsletter Email Sign Up By signing up you agree to receive email newsletters or updates from POLITICO and you agree to our privacy policy and terms of service. You can unsubscribe at any time and you can contact us here. This sign-up form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Presented by CVS Health With David Lim, Brianna Ehley and Emily Martin PROGRAMMING NOTE: Prescription Pulse will not publish from Friday, Dec. 25 to Friday, Jan. 1. We'll be back on our normal schedule on Monday, Jan. 4. See you in 2021!